TAFRO Syndrome

Hematol Oncol Clin North Am. 2018 Feb;32(1):107-118. doi: 10.1016/j.hoc.2017.09.009.

Abstract

TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Thrombocytopenia and severe anasarca accompanied by relatively low serum immunoglobulin levels are characteristic clinical findings of TAFRO syndrome that are not present in iMCD-not otherwise specified (iMCD-NOS). Lymph node biopsy is recommended to exclude other diseases and to diagnose TAFRO syndrome, which reveals characteristic histopathological findings similar to hyaline vascular-type CD. TAFRO syndrome follows a more aggressive course, compared with iMCD-NOS, and there is no standard treatment.

Keywords: Castleman disease; Clinical features; Pathogenesis; TAFRO syndrome.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Castleman Disease* / diagnosis
  • Castleman Disease* / pathology
  • Edema* / diagnosis
  • Edema* / pathology
  • Fever* / diagnosis
  • Fever* / pathology
  • Humans
  • Syndrome
  • Thrombocytopenia* / diagnosis
  • Thrombocytopenia* / pathology

Supplementary concepts

  • Multi-centric Castleman's Disease